PAPER Benedetto G, Zannino C, Valente D, Covello R, Scalise S, Lucchino V, Quattrone A, Parrotta EI, Quattrone A, Cuda G
SEARCH RESULTS
347560 RESULTS
PAPER Tamburrino L, Tafuri B, Gnoni V, Nigro S, Giugno A, Urso D, Zoccolella S, Filardi M, Logroscino G
Actigraphy validation in behavioral variant frontotemporal dementia.
Sleep Med. 2025 Feb;126:178-184. Epub 2024 Dec 10 PubMed.PAPER Singh S, Khan S, Shahid M, Sardar M, Hassan MI, Islam A
Targeting tau in Alzheimer's and beyond: Insights into pathology and therapeutic strategies.
Ageing Res Rev. 2025 Feb;104:102639. Epub 2024 Dec 16 PubMed.PAPER Arslan-Sarımehmetoğlu E, Gönen-Şentürk S
Evaluation of Depression and Perceived Voice Handicap Through Self-Report in Individuals With Alzheimer's Disease.
J Voice. 2024 Dec 13; Epub 2024 Dec 13 PubMed.Yaning Wang on Is It Time to Approve Drugs Based on Amyloid Removal?
COMMENT I was the director of FDA’s Division of Pharmacometrics before I left FDA in 2021. In July this year, I watched the presentation by Dr. Kevin Krudys, Associate Director, Office of Neuroscience, CDER, FDA, titled "Recent Examples of Reasonably Likely
Jaoud Ansari
Jamia Millia Islamia
India
Tobias Madl on ‘MGWAS’ Ties Brain Metabolites to Alzheimer’s, Parkinson’s, More
COMMENT This publication presents a comprehensive genome-wide association study on brain and CSF metabolite levels, and reveals significant metabolic changes associated with various diseases, including Alzheimer’s. The authors have also developed a webserver that
PAPER Klein J
Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids.
J Neural Transm (Vienna). 2000;107(8-9):1027-63. PubMed.Dennis Selkoe on Is It Time to Approve Drugs Based on Amyloid Removal?
COMMENT We are grateful for the numerous comments to our 12-author Perspective that have been posted on Alzforum through December 12. They provide thoughtful analyses and critiques of our provocative proposal of full regulatory approval of new amyloid-lowering im
Stanley Williams
University of Leeds
PAPER Chawla S, Molin M, Nystrom T
Tuning beneficial calcineurin phosphatase activation to counter α-synuclein toxicity in a yeast model of Parkinson's disease.
Neural Regen Res. 2025 Jan 1;20(1):199-200. Epub 2024 Apr 3 PubMed.PAPER Gunawardena S
Alpha-synuclein in mitochondrial dysfunction: opportunities or obstacles.
Neural Regen Res. 2025 Jan 1;20(1):197-198. Epub 2024 Apr 3 PubMed.Yaning Wang
Rui Ning Kang Pharma
China
PAPER Su Y, Wang Q, Gao F, Xu J, Fu J, Ying Y, Xia Y, Wang X, Dong Q, Shen Y, Cheng X
Increased Plasma β-Secretase 1 Activity Correlates With Neurodegeneration in Cerebral Small Vessel Disease.
J Am Heart Assoc. 2024 Dec 17;13(24):e036204. Epub 2024 Dec 14 PubMed.PAPER Li X, Chen Q, Zou X, Shen M, Han Z
The comparative analysis between sporadic and genetic Creutzfeldt-Jakob disease in China.
Acta Neurol Belg. 2024 Dec 14; Epub 2024 Dec 14 PubMed.Current Filters
- Date Range : All x